Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Avacta Group, Biocept, Caremindr, Cortechs, Cytiva, Docbot, Erba Mannheim, Fluidigm, Global Wholehealth Partners, Incontext.ai, Integrated Genetics, Life Image, PCORI, RapidAI, Senzime, Smiths Medical, Subtle Medical, Sugarmate, Tandem Diabetes Care, Windtree Therapeutics.
Redhill Biopharma Ltd.’s chief operating officer, Gilead Raday, told BioWorld that the firm will build on positive results in severe COVID-19 patients with oral opaganib, a first-in-class sphingosine kinase-2 inhibitor.
Just the name, Strategic National Stockpile (SNS), evokes the image of a huge warehouse, or a series of warehouses spread across the U.S., strategically stocked with all the medical supplies, diagnostics and drugs that will be needed nationwide to respond to any health emergency brought on by terrorists, nuclear attacks, pandemics or other public health hazards. The reality is so much more – and so much less.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Fulcrum, GBT, Hemoshear, Imara, Innate, Mayne, Medigene, Neurorx, Novartis, Relief, Philogen.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alteogen, Berlin Cures, Brainstorm Cell, Chemocentryx, Delmar, Evotec, GW, Ignova, Immunomic, Inxmed, Kymera, La Jolla, Lion TCR, Mateon, Melior, Repertoire, Replicate, Roivant, Scancell, Zealand, Zelluna.
Countries and health care providers should hope for the best but prepare for the worst as a resurgence of COVID-19 is expected in the fall, just as the influenza season hits.
BEIJING – Chinese state-backed vaccine developer China National Biotec Group (CNBG), of Beijing, said on June 16 that its inactivated COVID-19 vaccine candidate produced a seroconversion rate of up to 100% in a phase I/II trial that enrolled 1,120 healthy subjects.
HONG KONG - Mumbai-based Glenmark Pharmaceuticals Ltd. has been granted manufacturing and marketing approval for the launch of its antiviral drug, favipiravir, for the treatment of mild to moderate COVID-19, a move it deems a “landmark development for COVID-19 patients in India.”
RSS
